Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Net Income: 2021-2025

Historic Net Income for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $18.4 million.

  • Kiniksa Pharmaceuticals International's Net Income rose 245.24% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.9 million, marking a year-over-year increase of 142.99%. This contributed to the annual value of -$43.2 million for FY2024, which is 28.48% up from last year.
  • Kiniksa Pharmaceuticals International's Net Income amounted to $18.4 million in Q3 2025, which was up 3.38% from $17.8 million recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Net Income peaked at $224.1 million during Q3 2022, and registered a low of -$49.5 million during Q1 2021.
  • For the 3-year period, Kiniksa Pharmaceuticals International's Net Income averaged around -$5.3 million, with its median value being -$8.9 million (2024).
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Net Income skyrocketed by 833.67% in 2022, and later plummeted by 155.63% in 2023.
  • Kiniksa Pharmaceuticals International's Net Income (Quarterly) stood at -$44.1 million in 2021, then spiked by 300.84% to $88.5 million in 2022, then tumbled by 155.63% to -$49.2 million in 2023, then spiked by 81.95% to -$8.9 million in 2024, then surged by 245.24% to $18.4 million in 2025.
  • Its Net Income stands at $18.4 million for Q3 2025, versus $17.8 million for Q2 2025 and $8.5 million for Q1 2025.